Literature DB >> 15368057

[Soft tissue sarcoma].

P-U Tunn1, B Gebauer, J Fritzmann, M Hünerbein, P M Schlag.   

Abstract

Soft tissue sarcomas are characterized by their heterogeneity. With new diagnostic imaging techniques, low- and high-grade components of the tumor can be differentiated. Thus biopsies should be guided by imaging to assure representative specimens. Besides histopathology, the advent of chromosomal and gene expression analysis may allow more accurate classification in the near future. Gene expression profiling has already proven its value by finding new subclassifications in other tumor types. Furthermore, this technique is a promissing tool to predict the response of a tumor to neoadjuvant and adjuvant therapy. Up to now, response evaluation in neoadjuvant therapy is based on tumor size and not on vital tumor cells. Newer techniques (i.e., Magnetic-resonance-Spectroscopy, Molecular Imaging) can show the change of metabolism in neoadjuvant therapy and allow objective, comparative measurement of biological activity. The diagnostic of soft tissue sarcomas implies primarily a multidisciplinary approach for a stage associated therapy.

Entities:  

Mesh:

Year:  2004        PMID: 15368057     DOI: 10.1007/s00104-004-0914-9

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  37 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Clinical impact of molecular and cytogenetic findings in synovial sarcoma.

Authors:  I Panagopoulos; F Mertens; M Isaksson; J Limon; P Gustafson; B Skytting; M Akerman; R Sciot; P Dal Cin; I Samson; M Iliszko; J Ryoe; M Dêbiec-Rychter; A Szadowska; O Brosjö; O Larsson; A Rydholm; N Mandahl
Journal:  Genes Chromosomes Cancer       Date:  2001-08       Impact factor: 5.006

Review 3.  [Prognostic factors in soft tissue sarcoma in the adult].

Authors:  L Guillou; J M Coindre
Journal:  Ann Pathol       Date:  1997-12       Impact factor: 0.407

4.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

5.  Molecular characterisation of soft tissue tumours: a gene expression study.

Authors:  Torsten O Nielsen; Rob B West; Sabine C Linn; Orly Alter; Margaret A Knowling; John X O'Connell; Shirley Zhu; Mike Fero; Gavin Sherlock; Jonathan R Pollack; Patrick O Brown; David Botstein; Matt van de Rijn
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

6.  Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma.

Authors:  Germaine R Johnson; Hongming Zhuang; Jehanzeb Khan; Stephen B Chiang; Abass Alavi
Journal:  Clin Nucl Med       Date:  2003-10       Impact factor: 7.794

Review 7.  The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.

Authors:  E Bastiaannet; H Groen; P L Jager; D C P Cobben; W T A van der Graaf; W Vaalburg; H J Hoekstra
Journal:  Cancer Treat Rev       Date:  2004-02       Impact factor: 12.111

8.  Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas.

Authors:  J D Lucas; M J O'Doherty; J C Wong; J B Bingham; P H McKee; C D Fletcher; M A Smith
Journal:  J Bone Joint Surg Br       Date:  1998-05

9.  Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses.

Authors:  I Ray-Coquard; D Ranchère-Vince; P Thiesse; H Ghesquières; P Biron; M-P Sunyach; M Rivoire; L Lancry; P Méeus; C Sebban; J-Y Blay
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

10.  18FDG PET scanning of benign and malignant musculoskeletal lesions.

Authors:  Frieda Feldman; Ronald van Heertum; Chitra Manos
Journal:  Skeletal Radiol       Date:  2003-03-11       Impact factor: 2.199

View more
  4 in total

1.  Tumor rupture predicts early metastasis and poor prognosis in stage III soft tissue sarcomas.

Authors:  Yong Chen; JiHui Hao; Yun Yang; JiLong Yang; XiShan Hao
Journal:  World J Surg       Date:  2011-05       Impact factor: 3.352

2.  [Soft-tissue sarcoma of the forearm and hand. Plastic surgical management].

Authors:  M Müller; B Bickert; G Germann; M Sauerbier
Journal:  Chirurg       Date:  2008-07       Impact factor: 0.955

3.  The role of ultrasound-guided needle biopsy in the diagnosis of soft-tissue tumors.

Authors:  M Battaglia; P Pollastri; A Ferraro; F Betoni; G Bacci; S Galletti
Journal:  J Ultrasound       Date:  2007-05-25

4.  Radiographic response to neoadjuvant therapy and its impact on scope of surgery and prognosis in stage IIB/III soft tissue sarcomas.

Authors:  Yong Chen; Yun Yang; ChunMeng Wang; YingQiang Shi
Journal:  BMC Cancer       Date:  2013-12-11       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.